Results 101 to 110 of about 355,535 (359)

In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding

Frontiers in Pharmacology, 2017
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia, is limited by moderate efficacy and adverse side effects including ventricular proarrhythmia and organ toxicity.
Nicholas Ellinwood, Dobromir Dobrev, Stefano Morotti, Eleonora Grandi   +3 more
doaj   +1 more source

Rate-Control or Rhythm-Contol: Where do we stand? [PDF]

, 2005
Atrial fibrillation is the most common sustained rhythm disturbance and its prevalence is increasing worldwide due to the progressive aging of the population.
A, Dello Russo, F, Andreotti, F, Bellocci, G, Pelargonio, G, Trotta, L, Testa, M, Casella   +6 more
core   +1 more source

Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial

European Journal of Heart Failure, EarlyView.
Summary of the change in left ventricular systolic and diastolic parameters from baseline to 12 months in patients with permanent atrial fibrillation (AF) and a left ventricular ejection fraction (LVEF) ≥50%. P‐values indicate the significance of the adjusted mean difference of the parameters at 12 months between the beta‐blocker and digoxin arm. E/e′,
Karina V. Bunting, Asgher Champsi, Simrat K. Gill, Khalil Saadeh, A. John Camm, Mary Stanbury, Sandra Haynes, Jonathon N. Townend, Richard P. Steeds, Dipak Kotecha, on behalf of the RAte control Therapy Evaluation in Permanent Atrial Fibrillation (RATE‐AF) Trial Group   +10 more
wiley   +1 more source

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity

Molecules
Anthracyclines play an irreplaceable role in cancer treatment, although their clinical application is limited due to severe side effects such as arrhythmia, cardiomyopathy, and myocardial infarction.
Rongrong Bai, Zhigao Zhao, Xing Han, Mingying Shang, Guangxue Liu, Feng Xu, Shaoqing Cai   +6 more
doaj   +1 more source

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and of the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA has expanded therapeutic options for this population. This expert consensus
Luca Monzo, Gianluigi Savarese, Wilfried Mullens, Amr Abdin, Biykem Bozkurt, Ovidiu Chioncel, Seif El Hadidi, Thomas M. Gorter, Riccardo M. Inciardi, Mark C. Petrie, Gabriele G. Schiattarella, Davide Stolfo, Marco Metra, Nicolas Girerd   +13 more
wiley   +1 more source

Interactions between atrial fibrosis and inflammation in atrial fibrillation

Frontiers in Cardiovascular Medicine
Atrial fibrillation (AF) is a complex arrhythmia driven by intricate pathophysiological mechanisms, with atrial fibrosis and inflammation emerging as central players in its initiation and perpetuation.
Zhihua Pang, Ying Ren, Zhuhua Yao
doaj   +1 more source

Advances in Conductive Nanomaterials for Cardiac Arrhythmia and Future Directions in Bioevaluation Strategies. [PDF]

Adv Healthc Mater
Conductive nanomaterials (CNMs) show promising potential in cardiac tissue regeneration and restoring cardiac rhythm as reported in several in vitro studies. This review article elaborates on the applications of CNMs in the treatment of myocardial infarction (MI) and MI‐induced cardiac arrhythmias, and it sheds light on the innovative approach of ...
Srinivasan SY, Laromaine A.
europepmc   +2 more sources

Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations. [PDF]

, 2019
Drug-induced block of the cardiac rapid delayed rectifying potassium current (I Kr), carried by the human ether-a-go-go-related gene (hERG) channel, is the most common cause of acquired long QT syndrome.
Chen, I-Shan, Furutani, Kazuharu, Handa, Kenichiro, Kurachi, Yoshihisa, Sack, Jon T, Tsumoto, Kunichika, Yamakawa, Yuko   +6 more
core   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source

Artificial intelligence in preclinical epilepsy research: Current state, potential, and challenges

Epilepsia Open, EarlyView.
Abstract Preclinical translational epilepsy research uses animal models to better understand the mechanisms underlying epilepsy and its comorbidities, as well as to analyze and develop potential treatments that may mitigate this neurological disorder and its associated conditions. Artificial intelligence (AI) has emerged as a transformative tool across
Jesús Servando Medel‐Matus, Cesar Santana‐Gomez, Ruby G. Escalante, Dominique Duncan, Pedro F. Viana, Giulia Sofia Cereda, Naoto Kuroda, Aristea S. Galanopoulou   +7 more
wiley   +1 more source